Bedrocan produces five strains of medicinal cannabis ‘flos’ – the technical term for the whole, dried female flower. Each strain is standardised according to pharmaceutical standards with a consistent composition of cannabinoids and terpenes. Our cannabis products are independently tested for desired properties by specialised laboratories. The products currently available are listed below.
Are you a patiënt and in need of medicinal cannabis, please get in touch with the Dutch Office for Medicinal Cannabis at all times. You can not order Bedrocan products directly from us. Please check our contact page for the details.
THC 22% | CBD <1.0%
THC 13.5% | CBD <1.0%
THC 6.3% | CBD 8%
THC 14% | CBD <1.0%
THC <1.0% | CBD 9%
Introduced in 2003, Bedrocan® is the brand name for the cultivar Cannabis sativa L. ‘Afina’.
Cannabis sativa L. ‘Afina’ is the first cultivar developed and it features 22% THC, with a CBD-level below 1%. It’s the most widely used medicinal cannabis product and has been used in more research than other products.
Bedrocan® is available in flos form.
Introduced in 2005, Bedrobinol® is the brand name for the cultivar Cannabis sativa L. ‘Ludina’.
Cannabis sativa L. ‘Ludina’ is bred in-house by Bedrocan. Its THC-level can be considered medium strength, standardised at 13,5%, with a CBD-level below 1 %.
Bedrobinol® is available in flos form.
Introduced in 2007, Bediol® is the brand name for the cultivar Cannabis sativa L. ‘Elida’.
Cannabis sativa L. ‘Elida’ is one of the first cannabis cultivars developed specifically to have a higher CBD content. The effects of CBD are distinctly different from THC.
Bediol® has a balanced ratio of THC 6.3% and CBD 8%. Because it is easily tolerated, physicians often prescribe Bediol® for patients who previously have not used cannabis as a medicine. The ‘Elida’ cultivar was bred in-house by Bedrocan, specifically to meet the needs of patients.
Bediol® is available in granular form.
Introduced in 2011, Bedica® is the brand name for the indica cultivar Cannabis sativa L. ‘Talea’.
Cannabis sativa L. ‘Talea’ was developed in response to mounting evidence of a real difference in the effects of sativa and indica types.
Characteristic differences between indica and sativa cultivars can be found in the presence of aromatic compounds (terpenes) in the plant. Bedica® contains a high amount of the myrcene terpene, which is known to have a calming effect.
Bedica® contains 14% THC with less than 1% CBD.
Bedica® is available in granular form.
Introduced in 2014, Bedrolite® is the brand name for the cultivar Cannabis sativa L. ‘Rensina’.
Cannabis sativa L. ‘Rensina’ is a so-called CBD-only product, with less than 1% THC and 9% CBD. The virtual absence of THC means it does not have psychoactive properties. Bedrolite® has become the preferred choice of a number of patients with severe, intractable (untreatable) forms of epilepsy.
Bedrolite® is available in granular form.
In a recent study, the specific Bedrocan products that Dutch patients use on prescription were compared with the indications they suffered from. The graphs below show the most commonly reported indications, classified by the Bedrocan product used. The Y-axis values can be interpreted as the percentage of patients using a specific cannabis product (respondents could select multiple products).
For almost all indications, the product Bedrocan is the most commonly used.
According to the Dutch Office of Medicinal Cannabis (OMC), inhaled cannabis with a high CBD level (such as Bediol) is considered appropriate for symptoms such as pain, spasms and inflammation, which often occur with MS patients. It is also used by patients with other illnesses and symptoms. In particular, the OMC advises to begin with Bediol when suffering from chronic nerve pain.
Dosage varies from patient to patient. It is important that the dosage is titrated (built up) slowly, whichever product is used. It is important to find the right dose for each individual patient in order for them to fully benefit from medicinal cannabis. Most unwanted side effects of medicinal cannabis may be prevented by following just a few simple guidelines:
- Low dose – it is better to take several small doses in a day that add up to the required result, than to experiment with one single large dose.
- Patience – cannabis may have a different effect on each patient. Wait for the effect (if any) to appear. It’s best to use the same (low) dose for several days, and monitor any effects that may occur.
- Increase dose slowly – after a few days the patient can increase the dose, but slowly. Take a few days after each increase to monitor progress.
In about 1-2 weeks the patient should be able to find their own, personalised dose that gives the greatest medicinal effects with minimum side effects.